Roche: ends collaboration with France's Voluntis

(CercleFinance.com) - France's Voluntis has said that it will terminate a collaboration with Swiss pharma giant Roche to develop and distribute digital therapeutics for the treatment of breast cancer.


The collaboration between Roche and Voluntis will end on the conclusion of the feasibility clinical study currently being conducted by Roche, at the end of April 2019.

The deal between Roche and Voluntis, which was signed in October 2015, aimed to sell the Zemy solution in breast cancer, based on Voluntis' Theraxium technology platform that helps patients to self-manage their treatment.

Copyright (c) 2019 CercleFinance.com. All rights reserved.